相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency
Andrew S. Levey et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2020)
Effects of the chymase inhibitor fulacimstat on adverse cardiac remodeling after acute myocardial infarction-Results of the Chymase Inhibitor in Adverse Remodeling after Myocardial Infarction (CHIARA MIA) 2 trial
Hans-Dirk Duengen et al.
AMERICAN HEART JOURNAL (2020)
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
V. Perkovic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials
Hiddoj L. Heerspink et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Safety and Tolerability of the Chymase Inhibitor Fulacimstat in Patients With Left Ventricular Dysfunction After Myocardial Infarction-Results of the CHIARA MIA 1 Trial
Hans-Dirk Duengen et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2019)
Chymase inhibition retards albuminuria in type 2 diabetes
Benjamin J. Bivona et al.
PHYSIOLOGICAL REPORTS (2019)
Pharmacokinetics, Safety, and Tolerability of the Novel Chymase Inhibitor BAY 1142524 in Healthy Male Volunteers
Friederike Kanefendt et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2019)
Multifunctional Role of Chymase in Acute and Chronic Tissue Injury and Remodeling
Louis J. Dell'Italia et al.
CIRCULATION RESEARCH (2018)
Creatinine- versus cystatin C-based renal function assessment in the Northern Manhattan Study
S. Ali Husain et al.
PLOS ONE (2018)
Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease
Merlin C. Thomas et al.
NATURE REVIEWS NEPHROLOGY (2016)
Role of chymase in diabetic nephropathy
Priscila C. Cristovam et al.
EXPERIMENTAL BIOLOGY AND MEDICINE (2012)
Impact of Mast Cell Chymase on Renal Disease Progression
Haimanot Wasse et al.
CURRENT HYPERTENSION REVIEWS (2012)
Inhibition of chymase protects against diabetes-induced oxidative stress and renal dysfunction in hamsters
Yasutaka Maeda et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2010)
ACE-Dependent and chymase-dependent angiotensin II generation in normal and glucose-stimulated human mesangial cells
Priscila C. Cristovam et al.
EXPERIMENTAL BIOLOGY AND MEDICINE (2008)
Diabetic nephropathy: The proteinuria hypothesis
ME Williams
AMERICAN JOURNAL OF NEPHROLOGY (2005)
Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy
D de Zeeuw et al.
CIRCULATION (2004)
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL
D de Zeeuw et al.
KIDNEY INTERNATIONAL (2004)
Chymase is upregulated in diabetic nephropathy: Implications for an alternative pathway of angiotensin II - Mediated diabetic renal and vascular disease
XR Huang et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2003)
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
BM Brenner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
EJ Lewis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
分享论文
